You Position: Home > Paper

The clinical study of weekly docetaxel combined with cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer

( views:194, downloads:4 )
Author:
No author available
Journal Title:
CHINA CLINICAL PRACTICAL MEDICINE
Issue:
12
DOI:
10.3760/cma.j.issn1673-8799.2010.12.49
Key Word:
进展期胃癌;多西紫杉醇;顺铂;Advanced gastric cancer(AGC);Docetaxel(TXT);Cisplatin(DDP)

Abstract: Objective To evaluate the efficacy and toxicity of docetaxel(TXT) plus cisplatin(DDP) for patients with metastatic or recurrent advanced gastric cancer(AGC), previously treated with FOLFOX4 or XELOX regimen. Methods Twenty-seyen patients were treated with docetaxel (35 mg/m2 on day 1 and 8)and cisplatin (20 mg/m2 on days 1 to 5) every 3 weeks. Results Of the 36 patients qualified for efficacy analysis,the overall response rate was 27. 8% , including 10 cases of PR, 12 cases of SD and 14 cases of PD respectively. The median time to progression was 4. 4 months and median survival time was 6. 5 months. The predominant toxicity was hematologic, with neutrop enia. Non-hematological toxicity was rarely severe. Conclusion Combination chemotherapy with TXT/DDP given on 2 out of 3 weeks is well tolerated and active in heavily pretreated patients with AGC, even after prior exposure to OXA and 5-FU.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn